Novel Approach to Continuation of Elective Procedures in People at Risk for Sodium–Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Ketoacidosis

What is it about?

Diabetic ketoacidosis (DKA) is a serious side effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i), a type of antidiabetic medication. The risk of developing DKA is increased during procedures, so patients taking SGLT2i are told to discontinue the medication 3-4 days before their procedure. For situations where patients inadvertently continue their SGLT2i, we developed a simple algorithm for evaluating the risk of continuing with the procedure.

Featured Image